Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.125 1.26% 10.025 9.80 10.25 10.025 9.85 9.85 81,909 09:02:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.4 -6.3 -1.5 - 43

Kromek Share Discussion Threads

Showing 6376 to 6398 of 6400 messages
Chat Pages: 256  255  254  253  252  251  250  249  248  247  246  245  Older
DateSubjectAuthorDiscuss
29/6/2022
10:38
I expect Simon Thompson May article has been aired. He puts the current plight down to supply issues: Sedgefield-based Kromek (KMK:9.75p), a radiation detection technology company focused on the medical imaging and nuclear markets, has reported accelerating growth across both business segments. Buoyed by £5.9mn of contract wins in the last three months of the 2021/22 financial year, the directors expect a near 50 per cent ramp up in revenue to £18mn in the 12 months to 30 April 2023. Importantly, 50 per cent of the revenue forecast is already contracted, 37 per cent is going through contract negotiation and the balance represents repeat orders. The recent contract awards have been partly driven by increasing interest for Kromek’s chemical, biological, radiological and nuclear (CBRN) detectors from governments. I can only see demand gaining further momentum given the current geopolitical environment and the need for multiple sovereign states to step up their national security as an urgent priority. The directors also report high demand for the group’s cadmium zinc telluride (CZT) based products from original equipment manufacturers (OEMs) in the medical imaging industry. Following Canon’s acquisition of Redlen Technologies, medical imaging OEMs that adopting CZT technology in their next generation x-ray and gamma ray imaging products – Phillips and United Imaging, for example – are now far more reliant on Kromek, the only independent manufacturer of CZT. The strong demand that is now in evidence is slightly tempered by supply chain disruption. Specifically, the late arrival of certain components prevented £2.9mn worth of orders being completed in the 12 months to 30 April 2022. These will be shipped in the current financial year. As a result, the group will post a cash loss of £1.2mn on revenue of £12.1mn for the year just ended, an improvement on the prior year but shy of the breakeven result that Equity Development had anticipated. That said, Kromek looks incredibly well placed to return to profit in the new financial year when analysts pencil in a small cash profit of £0.3mn. Also, the unwinding of inventory and cash inflow from order completions will bolster gross cash of £5.1mn (excluding £6.5mn of borrowings) so the group is adequately funded to deliver on its order book. Moreover, it will not take too many additional CBRN wins from governments to deliver a material step change in profits given the high gross margin earned. I also expect Kromek to be awarded multi-year and multi-million dollar contracts from medical imaging OEMs looking to lock in surety of supply. So, although the news void since my last article has undermined investor confidence (‘Pivotal year unfolding for Kromek’, 18 January 2022), as more tenders are converted in major orders, a reappraisal of Kromek’s prospects should lead to a re-rating. New house broker finnCap has a 12-month target price of 27p, but sees scope for a move towards 40p as new orders are landed. Recovery buy.
estienne
20/6/2022
19:11
EQUITY RAISINGS SINCE £55m IPO dated 16/10/2013:- 1. 30/7/15 £11million 2. 25/1/17 £21million 3. 12/2/19 £21million 4. 12/2/21 £13million Time span between each consecutive equity raising ranges in a narrow band from 18-24 months. Since IPO , Kromek has never gone more than 24 months without tapping the market for further money/fresh equity. Time elapsed so far since last equity raising in Feb 2021 is SIXTEEN MONTHS. It will be interesting to watch whether this pattern repeats. Or whether it would even be possible at any reasonable valuation given the current deleterious state of the equity raising markets. ALL IMO. DYOR. QP
quepassa
16/6/2022
12:09
Basu took KMK from 51p to 10p over 9 years during a once in a lifetime bull market. Whats going to happen when markets tighten up?
ark87
12/6/2022
20:36
That’s someone from Tek Capitals group. I thought Kromek was bad enough, but check out the Tek board. Makes Kromek look like Microsoft
aqc888
10/6/2022
09:31
i filtered ac
ali47fish
01/6/2022
18:57
You’d think an investor would have clear evidence so that they could make their mind up if it worked or not. Why would that clear evidence not be available? Accreditation results they promised never released. Field trials they conducted not updated. Sales they promised not coming in. Either it doesn’t work or they’re completely and utterly incompetent. Given Kromeks history of the management being the latter, I still hold some hope the technology might actually work.
aqc888
01/6/2022
07:36
In one sentence the pathogen detector doesn't work and in the next there is a small chance, make your mind up! Fwiw kmk presented this to a formidable ordience in January IMO DYOR GLASP
slicethepie
01/6/2022
07:25
Im not sure why's anyone would state that one companies medical CT scannars are inferior to another's. Kromek's £57 million multi years contract to supply CZT equipment is for Philips almost certainly. and they are developing their own Photon Counting CT to release shortly from what I've read. This article from last year.. hTTps://www.diagnosticimaging.com/view/philips-launches-spectral-ct-7500-system hTTps://www.philips.co.uk/healthcare/product/HCNOCTN284/iqon-spectral-ct#:~:text=The%20IQon%20Spectral%20CT%20is,single%2C%20low%2Ddose%20scan
33mick
31/5/2022
23:29
Kromek has no value since it has no ability to make a profit. The hospital scanners are inferior to rival scanners. The biological pathogen detectors don’t work. The nuclear detectors are great but there’s no significant market or repeat orders for them. Kromek can sell the CZT other manufacturers need it would seem. But selling CZT and nuclear detectors doesn’t cover the CEOs spending requirements on new R&D. Hence the loss every year and constant fundraisings and need for government grants. There’s a small chance the biological pathogen detector works and an order might come in for it. But a much bigger chance there’s no order and Kromek runs out of cash.
aqc888
31/5/2022
22:41
Plus there's a lot of hospitals with old equipment due for replacement soon if this article is anything to go by. hTTps://www.dailymail.co.uk/news/article-10101859/NHS-scanners-x-ray-machines-ten-years-old-quarter-health-trusts
33mick
31/5/2022
22:36
My thoughts exactly slicethepie. The leap in medical imaging tech made possible with CZT and it's universal adoption by the major OEMs is never going to revert backwards it will only improve, the latest addition being AI to enhance the speed and accuracy again.the market is also larger than I realized with dental imaging, vetinary use and CT scans are very common in postmortems for help with cause of death and forensic examinations,.
33mick
31/5/2022
21:30
Our resident bears fail to understand that everything has value and the tide is turning for kmk. Clearly Basu has not delivered but he has built a business that has a value significantly higher than the current price generates. The fact that the end markets are slowly turning in their favour is an additional positive. Anyone who has dealt with the bodies that kmk deals with will know they are very slow at decision making. ALL IMHO. DYORSP
slicethepie
31/5/2022
21:27
Yes things seem to be turning for the better for long suffering shareholders. GLA
strategicinvestor2
31/5/2022
21:07
Kromek was sat in the epicentre of a pandemic with a supposedly unique detector. To fail to deliver any profits whatsoever from such an achievement is remarkable. To think Kromek will achieve future success is a ridiculous folly. The board know it, and proved it, by not buying any at 8p. Where’s the independent proof these biological detectors work? No proof, no sales = it’s blindingly obvious they don’t work and were used to lure in money at the last desperate fundraising.
aqc888
31/5/2022
07:53
Onwards and upwardsIMO DYOR GLASP
slicethepie
31/5/2022
07:13
Kromek is currently sat right place right time right products. This will translate in to a significantly higher share price imho
senttothegallows
31/5/2022
04:03
Hopefully we will hear more with the results on where they are at on restructuring the company divisionally that would facilitate carve out and separate valuation or potential take over of different parts of the business. This seems a sensible move for shareholders. Any view or knowledge on this ? Maybe already relatively separate ? IMHO DYOR
strategicinvestor2
27/5/2022
07:45
Does everyone who ever makes a post have to be a ramper or short? QP has been pro and anti Kromek over time, as have I. What’s driven the anti Kromek sentiment is the incompetence and misguidance of the board. There’s a possibility that things might turn around, but if it does, that turnaround will have nothing to do with the guidance the board issue. So much sheer nonsense has come out of their mouths, I’d rather have a donkey in the CEOs chair.
aqc888
26/5/2022
13:26
Can you repeat that please.
b00mb0y
26/5/2022
12:51
He who POSTS negatively most when price is rising is normally short ?ouchALL IMHO. DYORSP
slicethepie
26/5/2022
11:41
Remind me please. What is their visibility on PROFITABILITY for the next years. Because although they have MANY TIMES in the past said they have GOOD VISIBILITY on revenues - this has NEVER ONCE translated into profitability.
quepassa
26/5/2022
11:26
He who posts negatively most when price is rising is normally short ...ouchALL IMHO. DYORSP
slicethepie
26/5/2022
11:15
Remind me please. What is their visibility on PROFITABILITY for the next years. Because although they have MANY TIMES in the past said they have GOOD VISIBILITY on revenues - this has NEVER ONCE translated into profitability.
quepassa
Chat Pages: 256  255  254  253  252  251  250  249  248  247  246  245  Older
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220701 10:33:54